Sequential therapy with anti-thymocyte globulin and cyclosporine a in oligoanuric high-risk cadaveric kidney graft recipients
Valderrábano, F.; Anaya, F.; Robles, N.R.; Jofré, R.
Transplantation Proceedings 20(5 Suppl 6: 75-78
1988
ISSN/ISBN: 0041-1345 PMID: 3051597 Document Number: 308074
Document emailed within 1 workday
Related Documents
Hourmant, M.; Buzelin, F.; Dubigeon, P.; Soulillou, J.P. 1987: High long-term graft survival rates in kidney transplantation with the sequential association of antithymocyte globulin and cyclosporine A monotherapy Transplantation Proceedings 19(1 Pt 3): 2113-2114Widmer, U.; Frei, D.; Keusch, G.; Burger, H.R.; Largiader, F.; Binswanger, U. 1988: OKT3 treatment of steroid- and/or anti-thymocyte globulin-resistant renal allograft rejection occurring on triple baseline immunosuppression including cyclosporine a Transplantation Proceedings 20(5 Suppl 6: 90-95
Ludwin, D.; White, N.; Tsai, S.; Smith, E.K. 1985: Sequential Minnesota antilymphoblast globulin and cyclosporine therapy after cadaver renal transplantation Transplantation Proceedings 17(4): 1943-1944
Opelz, G.; Schwarz, V.; Engelmann, A.; Back, D.; Wilk, M.; Keppel, E. 1991: Long-term impact of HLA matching on kidney graft survival in cyclosporine-treated recipients Transplantation Proceedings 23(1 Part 1): 373-375
Busnach, G.; Stragliotto, E.; Minetti, E.; Perego, A.; Brando, B.; Broggi, M.L.; Civati, G. 1998: Effect of n-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients: a randomized placebo-controlled study Journal of Nephrology 11(2): 87-93
Alfonso, J.; Gralla, J.; Klem, P.; Chan, L.; Wiseman, A.C.; Cooper, J.E. 2014: High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts Clinical Transplants 2014: 161-170
Süsal, C.; Groth, J.; Tanzi-Fetta, R.F.; Kirste, G.; Doerr, C.; Terness, P.; May, G.; Staehler, G.; Opelz, G. 1992: Characterization of protective anti-Fab autoantibodies in kidney graft recipients Transplantation Proceedings 24(6): 2523-2526
Abbud-Filho, M.; Kupiec-Weglinski, J.W.; Araujo, J.L.; Heidecke, C.D.; Tilney, N.L.; Strom, T.B. 1984: Cyclosporine therapy of rat heart allograft recipients and release of interleukins (IL 1, IL 2, IL 3): a role for IL 3 in graft tolerance? Journal of Immunology 133(5): 2582-2586
Bonaros, N.E.; Kocher, A.; Dunkler, D.; Grimm, M.; Zuckermann, A.; Ankersmit, J.; Ehrlich, M.; Wolner, E.; Laufer, Günther. 2004: Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients Transplantation 77(6): 890-897
Wang, M.; Qu, X.; Stepkowski, S.M.; Chou, T.C.; Kahan, B.D. 1996: Beneficial effect of graft perfusion with anti-T cell receptor monoclonal antibodies on survival of small bowel allografts in rat recipients treated with brequinar alone or in combination with cyclosporine and sirolimus Transplantation 61(3): 458-464
Toledo-Pereyra, L.H.; Baskin, S.; McNichol, L.; Edford, G.; Whitten, J.; Allaben, R. 1980: Improved results in high risk cadaveric kidney transplantation Proceedings of the Clinical Dialysis and Transplant Forum 10: 289-292
Gilbert, C. 1984: Clinical uses of anti-thymocyte globulin (ATGAM), Part Ii North Carolina Medical Journal 45(12): 773-775
Sheil, A.G.; Disney, A.P.; Mathew, T.H.; Amiss, N.; Excell, L. 1991: Cancer development in cadaveric donor renal allograft recipients treated with azathioprine (AZA) or cyclosporine (CyA) or AZA/CyA Transplantation Proceedings 23(1 Part 2): 1111-1112
Sukhavasharin, N.; Praditpornsilpa, K.; Avihingsanon, Y.; Kuoatawintu, P.; O-Charoen, R.; Kansanabuch, T.; Tungsanga, K.; Eiam-Ong, S. 2006: Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose Journal of the Medical Association of Thailand 89(Suppl 2): S15-S20
Thomas, F.; Cunningham, P.; Thomas, J.; Gross, U.; Gaskins, D.; Sash, C.; Parker, K. 1987: Superior renal allograft survival and decreased rejection with early high-dose and sequential multi-species antilymphocyte globulin therapy Transplantation Proceedings 19(1 Pt 3): 1874-1878
Fisher, R.I.; Silver, B.A.; Vanhaelen, C.P.; Jaffe, E.S.; Cossman, J. 1982: Objective regressions of T- and B-cell lymphomas in patients following treatment with anti-thymocyte globulin Cancer Research 42(6): 2465-2469
Thomas, J.; Millington, M.; Volk, M.; Thomas, F.; Hume, D. 1974: Rabbit anti-human thymocyte globulin (RAHTG): in vitro and in vivo testing Transplantation Proceedings 6(4): 395-398
Brynger, H.; Persson, H.; Flatmark, A.; Albrechtsen, D.; Frödin, L.; Tufvesson, G.; Gäbel, H.; Weibull, H.; Möller, E.; Lundgren, G. 1988: No effect of blood transfusions or HLA matching on renal graft success rate in recipients treated with cyclosporine-prednisolone or cyclosporine-azathioprine-prednisolone: the Scandinavian experience Transplantation Proceedings 20(3 Suppl 3: 261-263
Teplan, V.; Schueck, O.; Nádvorníková, H.; Kocandrle, V. 1991: Metabolic disorders in cadaveric kidney donors and initial nonfunction of the kidney graft Transplantation Proceedings 23(5): 2619
Lundgren, G.; Albrechtsen, D.; Brynger, H.; Flatmark, A.; Frödin, L.; Gäbel, H.; Lindholm, A.; Maurer, W.; Möller, E.; Persson, H. 1987: Role of HLA matching and pretransplant blood transfusions in cyclosporine-treated recipients of cadaveric renal allografts: 2- to 3-year results Transplantation Proceedings 19(5): 3614-3618